Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
VANCOUVER, British Columbia and WARMINSTER, Pa., April 30, 2018 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, May 3, 2018 at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss first quarter 2018 financial results and provide a corporate update.
To access the conference call, a live webcast of the call can be accessed through the Investor section of Arbutus' website at www.arbutusbio.com. Or, alternatively, to access the conference call, please dial 1-914-495-8556 or 1-866-393-1607.
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-404-537-3406 or 1-855-859-2056 and referencing conference ID 4169558.
About Arbutus
Arbutus Biopharma Corporation is a publicly traded (Nasdaq:ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B (HBV) infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care (SOC) and contribute to a curative combination regimen to improve patient outcomes and deliver a potential cure for HBV. For more information, visit www.arbutusbio.com.
Contact Information
Investors
Tiffany Tolmie
Manager, Investor Relations
Phone: 604-419-3200
Email: [email protected]
Media
David Schull
Russo Partners
Phone: 858-717-2310
Email: [email protected]
